Amova Asset Management Americas Inc. Buys 121,491 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Amova Asset Management Americas Inc. boosted its stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 49.1% during the first quarter, Holdings Channel reports. The institutional investor owned 368,828 shares of the company’s stock after buying an additional 121,491 shares during the period. Amova Asset Management Americas Inc.’s holdings in Compass Pathways were worth $2,029,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in CMPS. Persistent Asset Partners Ltd bought a new position in Compass Pathways during the 4th quarter worth $38,000. Parallel Advisors LLC raised its position in shares of Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Compass Pathways in the third quarter valued at approximately $41,000. North Star Investment Management Corp. boosted its stake in shares of Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after buying an additional 7,000 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Compass Pathways during the fourth quarter worth approximately $47,000. Institutional investors own 46.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CMPS. Maxim Group raised their price objective on Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. B. Riley Financial began coverage on Compass Pathways in a report on Friday, April 24th. They set a “buy” rating and a $17.00 target price on the stock. Raymond James Financial restated a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Tuesday, July 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Compass Pathways in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.15.

Compass Pathways Stock Up 4.4%

CMPS stock opened at $12.18 on Wednesday. The stock has a market capitalization of $1.64 billion, a P/E ratio of -3.87 and a beta of 2.47. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. Compass Pathways PLC Sponsored ADR has a 12 month low of $3.92 and a 12 month high of $15.40. The firm has a 50-day moving average price of $12.45 and a 200-day moving average price of $8.92.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. As a group, equities research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current fiscal year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.